Immuron Limited (IMRN)

9.66 +0.1399 (+1.47%)

IEX Real-Time Price

August 17, 2018 EST.

NASDAQ Capital Market : Healthcare

Prev Close 9.5201

Price Open 9.33

Volume: 1,151

Avg Volume: 8,881

Market Cap: 34.68M

P/E Ratio -

52 Wk Range 4.63-16.7



IMRN Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-07-31
3.59M
5,770
0.48
0.16%

2018-07-13
3.59M
3,456
0.42
0.10%

2018-06-29
3.59M
1,866
0.20
0.05%

2018-06-15
3.59M
6,780
0.70
0.19%




News

Your Daily Pharma Scoop: Biohaven In Pivotal Stage, Merck Trial Positive, FDA Waives EyeGate (2018-07-27 03:48 SeekingAlpha)

Biohaven launches Phase 2/3 study of trigriluzole in Alzheimer's Discussion : Biohaven Pharmaceutical Holding Company ( BHVN ) commences Phase 2/3 trial of its candidate BHV-4157 (trigriluzole) in patients with mild-to-moderate Alzheimer's disease (AD). Patient enrollment is expec…

 


Statistics

Shares Outstanding: 3.59M

Top 15 Institution Percent: 3.10

Price To Sales: 47.64

Price To Book: 9.59

Revenue: N/A

Gross Profit: N/A

Cash: N/A

Debt: N/A

Return On Assets: -85.85

Return On Equity: -106.07

Profit Margin: N/A

Price History

Beta: 2.15

50-day Moving Avg: 10.18

200-day Moving Avg: 8.54

YTD Change: 82.26

5-day Change: -1.93

1-month Change: -12.74

3-month Change: 11.68

6-month Change: 24.16

1-year Change: 69.47

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Immuron Limited

Exchange: NASDAQ Capital Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.immuron.com

Immuron Ltd is a biopharmaceutical company which develops polyclonal antibodies for the treatment and prevention of diseases. It products include Travelan, IMM-124E for NASH and IMM-529 for Clostridium difficile infection.